-
CancelDate：2023-06
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=706The round was led by New Alliance Capital and Zhangkeherun Venture Capital, with participation from new investors Rockbleu Capital, Royal Fund, Zhuhai Huajin Capital, and Elikon Venture, and continued support from existing investors Delos Global Investmen
-
CancelDate：2023-05
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=705Nantong Jinyu BOSIN Intelligent Technology Co., Ltd., ("BOSIN" or the "Company"), a leader in China's aerial robotics automation systems industry, recently closed an A+ financing round, raising tens of millions in RMB. Central Huijin Capital led the round
-
CancelDate：2023-04
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=708Columbia China and Nanyan Group announce Nanyan Group's acquisition of Columbia China's clinic business. CEC Capital acted as exclusive financial advisor to Columbia China in this transaction.
-
CancelDate：2023-04
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=711Shanghai Winning Health Software Technology Co., Ltd. ("Winning Health") recently raised RMB 300 million in its Series C financing round. The investment was led exclusively by Taiping Medical and Health Industry Fund, a subsidiary of China Taiping Insuran
-
CancelDate：2023-04
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=712Hangzhou Wanxiang Cultural Technology Co., Ltd. (" WanXiang Tech " or “Company”), a frontrunner in China's virtual content domain, successfully closed an A2 financing round worth tens of millions of RMB. In this funding round, existing shareholder Porsche Ventures increased its investment, and several strategic investment institutions also participated. CEC Capital acted as the exclusive financial advisor for Wanxiang Tech in this transaction.
-
CancelDate：2023-04
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=707Hangzhou Diagens Biotechnology Co., Ltd. ("Diagens Biotechnology" or "the Company"), a leading reproductive health company in China, recently closed a financing round of RMB 100+ million. This round was led by Grand Flight Investment, with participation f
-
CancelDate：2023-03
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=710Qingdao PHAGEPHARM Biotechnology Co., Ltd. ("PHAGEPHARM" or “Company”), a leading domestic provider of phage-resistant comprehensive solutions, completed a Series B financing round of nearly RMB 100 million. This financing was led by Cenova Capital, with participation from Morningside Ventures and two existing shareholders. CEC Capital served as exclusive financial advisor for this transaction.
-
CancelDate：2023-02
http://www.xinyucaifu.cn/index.php?a=shows&catid=34&id=713NEXIC Technology, a company specializing in silicon carbide (SiC) power semiconductors, recently secured several hundred million yuan through its Series B and B+ financing rounds. The round was led by Xinchao Innovation Investment Group and JP Xinchao Cap
-
Cancel
Scan to log in to WeChatLog in on phone to use WeChat on Web
京公網安備 11010102004518號